Deliver Your News to the World

co.don AG - world wide revolutionary Enhancement of Product Portfolio and Indication


co.don® AG – world wide revolutionary Enhancement of Product Portfolio and Indication: successful treatment of hip cartilage defects with autologous 3-dimensional cultured chondrocytes -co.don chondrosphere® (ACT 3D).

July 25th, 2006 - For the first time worldwide a hip cartilage defect was successfully treated by using autologous 3-dimensional cultured chondrocytes -co.don chondrosphere®– by Dr. Andrea Fontana and his assistant Dr. Antonio Giampaolo. Dr. Fontana is an international well-known hip joint expert and orthopaedic surgeon at Clinic St. Rita, Milano, Italy. With this therapeutic option, based on co.don´s proprietary spheroid technology, co.don offers the unique regenerative treatment option of several hip cartilage disorders.

German Biopharmaceutical company, co.don® AG (WKN: 517360) enhances its product portfolio with the application of autologous 3-dimensional cultured chondrocytes -codon chondrosphere®- (ACT -3D) for the regenerative treatment of the hip cartilage defects.

The proprietary spheroid technology of co.don® allows the highly simplified surgical application of autologous 3-dimensional cultured chondrocytes without any foreign scaffold- eather membrane or matrix of animal or synthetic origin. This is substantial clinical benefit leading not only to increased patient and surgeons acceptance and to enhanced symptom relief but modifying osteoarthritic cartilage via de-novo synthesized hyaline cartilage regenerate.

co.don® ensures a sustainable competitive product advantage with their new product – co.don chondrosphere®. In Germany it is marked under the brand “ARTROcell 3D” by ORMED GmbH & Co KG. In the Italian Market co.dons products are marked by XMEDICA S.R.L., Milan, Italy.

co.don® is the European leader in the development and application of strictly autologous human Tissue engineering therpaeutics for the regenerative treatment of lost or damaged tissues such as articular cartilage, intervertebral disc and bone.

According to the WHO, about 3 Million hip surgery treatments are performed annualy world wide, appr. 600,000 in U.S. and 140,000 in Germany.

Management co.don AG

co.don® AG is one of the leading biopharmaceutical companies in the area of Regenerative Medicine/Tissue Engineering. Since 1997, co.don® AG develops, manufactures and distributes human Tissue engineering therapeutics for the regeneration of articular cartilage, bone and intervertebral discs. The company is headquartered in Teltow, near Berlin, Germany. For more information, please visit


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.